Management Recommendation
Continue aripiprazole and add a mood stabilizer (lithium or lamotrigine) rather than discontinuing or switching the aripiprazole, as the patient has demonstrated response to aripiprazole for hypomania and now requires treatment for the depressive phase of bipolar disorder. 1
Rationale and Treatment Algorithm
Why Continue Aripiprazole
Aripiprazole successfully controlled the hypomanic symptoms, indicating the patient is a responder to this medication. The guidelines emphasize that treatment choice should be based on the patient's history of medication response 1. Discontinuing a medication that has proven effective for one pole of the illness would be premature.
Addressing the Depression
The core issue is that aripiprazole alone is FDA-approved only for acute mania in adults, not for bipolar depression 1. The guidelines clearly state that no single agent is approved by the FDA for treatment of all phases of bipolar disorder 1.
Evidence-Based Augmentation Strategy
For bipolar depression while maintaining mood stability:
First-line options:
- Add lithium (FDA-approved for maintenance therapy in bipolar disorder, age 12+) 1
- Add lamotrigine (FDA-approved for maintenance therapy in adults, with evidence for bipolar depression) 1
Alternative option:
- Switch to olanzapine-fluoxetine combination (FDA-approved specifically for bipolar depression in adults) 1
Critical Cautions
Avoid antidepressant monotherapy. The guidelines explicitly warn that antidepressants may be useful adjuncts for depression only as long as the patient is also taking at least one mood stabilizer, as antidepressants can destabilize mood or precipitate mania 1. This is particularly important given the patient's recent hypomania.
Dosing Considerations for Aripiprazole
If continuing aripiprazole, consider the current dose. Recent research suggests low doses of aripiprazole (2-5 mg) may be more effective and better tolerated than higher doses for bipolar depression 2, 3. The dose-response curve shows optimal efficacy between 2-5 mg, with no additional benefit at higher doses 3.
Common Pitfalls to Avoid
- Do not discontinue aripiprazole - This removes the only medication currently preventing hypomanic recurrence
- Do not add an antidepressant alone - High risk of mood destabilization or switching to mania 1
- Do not use high-dose aripiprazole - Evidence suggests diminishing returns and worse tolerability above 5 mg 2, 3
- Avoid unnecessary polypharmacy - While multiple agents are often required, the guidelines emphasize avoiding unnecessary combinations 1
Monitoring
Once augmentation is initiated, reassess within 2-4 weeks for depressive symptom improvement while monitoring for any return of hypomanic symptoms or treatment-emergent mania.